Literature DB >> 16640452

Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.

Mario Wurglics1, Manfred Schubert-Zsilavecz.   

Abstract

Hypericum perforatum (St John's Wort [SJW]) counts among the most favourite herbal drugs, and is the only herbal alternative to classic synthetic antidepressants in the therapy of mild to moderate depression. Several clinical studies have been conducted to verify the effectiveness of ethanolic or methanolic extracts of SJW. Alcoholic SJW extracts are a mixture of substances with widely varying physical and chemical properties and activities. Hyperforin, a phloroglucinol derivative, is the main source of pharmacological effects caused by the consumption of alcoholic extracts of SJW in the therapy of depression. However, several studies indicate that flavone derivatives, e.g. rutin, and also the naphthodianthrones hypericin and pseudohypericin, take part in the antidepressant efficacy. In contrast to the amount of documentation concerning clinical efficacy, oral bioavailability and pharmacokinetic data about the active components are rather scarce. The hyperforin plasma concentration in humans was investigated in a small number of studies. The results of these studies indicate a relevant plasma concentration, comparable with that used in in vitro tests. Furthermore, hyperforin is the only ingredient of H. perforatum that could be determined in the brain of rodents after oral administration of alcoholic extracts. The plasma concentrations of the hypericins were, compared with hyperforin, only one-tenth and, until now, the hypericins could not be found in the brain after oral administration of alcoholic H. perforatum extracts or pure hypericin. Until now, the pharmacokinetic profile of the flavonoids in humans after oral administration of an alcoholic H. perforatum extract has been investigated in only one study. More data are available for rutin and the aglycone quercetin after administration of pure substances or other flavonoid sources.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16640452     DOI: 10.2165/00003088-200645050-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  114 in total

1.  Development of a high-performance-liquid-chromatographic method for the determination of biapigenin in biorelevant media.

Authors:  S Schulte-Löbbert; K Westerhoff; A Wilke; M Schubert-Zsilavecz; M Wurglics
Journal:  J Pharm Biomed Anal       Date:  2003-09-15       Impact factor: 3.935

2.  [Neuroendocrinologic and endocrinologic research in depressive patients].

Authors:  F Holsboer; O Benkert
Journal:  Nervenarzt       Date:  1985-01       Impact factor: 1.214

3.  St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats.

Authors:  V Butterweck; H Winterhoff; M Herkenham
Journal:  Mol Psychiatry       Date:  2001-09       Impact factor: 15.992

4.  Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin.

Authors:  A J Day; F Mellon; D Barron; G Sarrazin; M R Morgan; G Williamson
Journal:  Free Radic Res       Date:  2001-12

5.  Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man.

Authors:  P C Hollman; J M van Trijp; M N Buysman; M S van der Gaag; M J Mengelers; J H de Vries; M B Katan
Journal:  FEBS Lett       Date:  1997-11-24       Impact factor: 4.124

6.  The interaction between St John's wort and an oral contraceptive.

Authors:  Stephen D Hall; Zaiqi Wang; Shiew-Mei Huang; Mitchell A Hamman; Nina Vasavada; Adegboyega Q Adigun; Janna K Hilligoss; Margaret Miller; J Christopher Gorski
Journal:  Clin Pharmacol Ther       Date:  2003-12       Impact factor: 6.875

7.  Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products.

Authors:  S Schulte-Löbbert; G Holoubek; W E Müller; M Schubert-Zsilavecz; M Wurglics
Journal:  J Pharm Pharmacol       Date:  2004-06       Impact factor: 3.765

8.  Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers.

Authors:  B Staffeldt; R Kerb; J Brockmöller; M Ploch; I Roots
Journal:  J Geriatr Psychiatry Neurol       Date:  1994-10       Impact factor: 2.680

9.  Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial.

Authors:  H Kiesewetter; J Koscielny; U Kalus; J M Vix; H Peil; O Petrini; B S van Toor; C de Mey
Journal:  Arzneimittelforschung       Date:  2000-02

10.  Adrenal gland volume in major depression: relationship to basal and stimulated pituitary-adrenal cortical axis function.

Authors:  R T Rubin; J J Phillips; J T McCracken; T F Sadow
Journal:  Biol Psychiatry       Date:  1996-07-15       Impact factor: 13.382

View more
  23 in total

1.  Taxonomy and Chemotaxonomy of the Genus Hypericum.

Authors:  Sara L Crockett; Norman K B Robson
Journal:  Med Aromat Plant Sci Biotechnol       Date:  2011-01

Review 2.  Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood-Cerebrospinal Fluid Barrier and Blood-Brain Barrier.

Authors:  Lilian W Kibathi; SoHyun Bae; Scott R Penzak; Parag Kumar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

3.  Hypericum caprifoliatum and Hypericum connatum affect human trophoblast-like cells differentiation and Ca(2+) influx.

Authors:  Aline O da Conceição; Gilsane Lino von Poser; Benoit Barbeau; Julie Lafond
Journal:  Asian Pac J Trop Biomed       Date:  2014-05

4.  Optimization of protein extraction from Hypericum perforatum tissues and immunoblotting detection of Hyp-1 at different stages of leaf development.

Authors:  Katja Karppinen; Erja Taulavuori; Anja Hohtola
Journal:  Mol Biotechnol       Date:  2010-11       Impact factor: 2.695

5.  Identification of light-independent inhibition of human immunodeficiency virus-1 infection through bioguided fractionation of Hypericum perforatum.

Authors:  Wendy Maury; Jason P Price; Melinda A Brindley; ChoonSeok Oh; Jeffrey D Neighbors; David F Wiemer; Nickolas Wills; Susan Carpenter; Cathy Hauck; Patricia Murphy; Mark P Widrlechner; Kathleen Delate; Ganesh Kumar; George A Kraus; Ludmila Rizshsky; Basil Nikolau
Journal:  Virol J       Date:  2009-07-13       Impact factor: 4.099

Review 6.  Ginkgo biloba extracts: a review of the pharmacokinetics of the active ingredients.

Authors:  Christian Ude; Manfred Schubert-Zsilavecz; Mario Wurglics
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

Review 7.  St John's wort for major depression.

Authors:  Klaus Linde; Michael M Berner; Levente Kriston
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

8.  Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort.

Authors:  Ute Gödtel-Armbrust; Annegret Metzger; Ulrike Kroll; Olaf Kelber; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-26       Impact factor: 3.195

9.  Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells.

Authors:  Faten Merhi; Ruoping Tang; Marion Piedfer; Julie Mathieu; Isabelle Bombarda; Murhaf Zaher; Jean-Pierre Kolb; Christian Billard; Brigitte Bauvois
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

Review 10.  [New developments in hypericum extracts: data on efficacy and interactions].

Authors:  Karin Kraft
Journal:  Wien Med Wochenschr       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.